
BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
Silvia Deaglio, M.D., Ph.D.	Assistant Professor of Medical Genetics

EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
University of Torino, Italy	M.D.	1992-1998	Medicine
University of Torino, Italy	Board Certification	1998-2002	Oncology
University of Torino, Italy	Ph.D.	2002-2006	Genetics

Positions and Employment

- 1993-1998: Internal student, Laboratory of Cell Biology, Department of Genetics, Biology and Biochemistry, University of Torino.
- 1999-2002: Oncology fellow, Oncology Division, Molinette Hospital, Torino, Italy.
- 2002-2004: Clinical attending physician, Breast Cancer Clinic, Oncology Division, Molinette Hospital, Torino, Italy.
- 2002-2006: Ph.D. student (Genetics), Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino.
- 2004-: 2005 Instructor in Medicine and (2005) Visiting Assistant Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
- Jan 2005-: Assistant Professor of Medical Genetics (“Ricercatore”, “Confermato” since Jan 1, 2008), University of Torino Medical School, Torino, Italy.
- Sept 2010-: Head of the Immunogenetics Research Unit of the Human Genetics Foundation (www.hugef-torino.org), Turin, Italy.
- Oct 2011-: Associate Professor of Medical Genetics, University of Torino Medical School, Torino, Italy.

Other Professional Experience

- 1995: Visiting medical student, Sloan Kettering Cancer Center, New York, NY.
Reference: Dr. Michael Meyers and Dr. Alan N. Houghton
- 2001: Visiting scientist, Department of Cell Biology and Immunology, Instituto Parasitologia y Biomedicina, C.S.I.C., Granada, Spain. Reference: Drs. Mercedes Zubiaur and Jaime Sancho
- 2002: Visiting scientist, Department of Hematology, University of Essen Medical School, Essen, Germany. Reference: Dr. Ulrich Duerhsen.
- 2007: Visiting scientist, The Feinstein Institute for Medical Research, North Shore Long Island Jewish Health System, Manhasset New York, NY. Reference: Dr. N. Chiorazzi.

Professional Memberships

- 2003-: American Association for Cancer Research (full member)
- 2004-: American Association of Immunologists (full member)
- 2008-: Italian Society for Experimental Hematology (full member)
- 2008-: American Association of Hematologists (full member)
- 2009-: Member of the European Research Initiative on CLL (ERIC)
- 2010-: Member of the Henry Kunkel Society

Reviewer and Editorial activities for:

Blood

Leukemia

Cancer Research

Haematologica

Molecular Medicine

Leukemia and Lymphoma

Leukemia Research

Expert Reviews in Hematology

Purinergic Signaling

Journal of Transplantation

- 2008-: Member of the Editorial Board "Current Signal Transduction Therapy"
(<http://www.bentham.org/cstt/EBM.htm>)

Teaching Duties

- Course on Medical Genetics, Corso di Laurea in Scienze Infermieristiche (Torino and Ivrea), Università degli Studi di Torino (since 2005).
- Co-teacher in the Course on Human Genetics, Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Torino (since 2002).
- Board of the PhD School on Scienze Biomediche e Oncologia Umana, Università degli Studi di Torino (since 2005).

Honors

- 1996: PBI international Prize for the best abstract presented at the 1996 Immunology Cooperation Group (GCI) meeting in L'Aquila, Italy.
- 1998: Telethon Foundation Prize for scientific research, Roma, Italy.
- 1999: Optime Prize for best qualified students, Industrial Association of Torino. Torino, Italy.
- 2002: Cecilia Cioffrese prize for cancer research (Milano, Italy)
- 2004: Walter Knapp Young Investigator Award. Prize presented at the VIII HLDA Congress, December 10-14, 2004, Adelaide, Australia.
- 2006: Italian Cancer League Prize for translational researches in hematology (Asti, October 18, 2006)

Selected seminars and invited lectures

2004:

Seminar at the San Raffaele Biomedica Park Foundation, Rome, February 2004.

Invited Speaker at the 8th HLDA Meeting, Adelaide Australia, December 2004

2005:

Seminar at the Trudeau Institute, Saranac Lake, NY, August 2005

Internal Seminars, Department of Immunology, Beth Israel Deaconess Medical Center, Boston, MA

2006:

Invited speaker at the "Purines 2006" meeting, Ferrara, May 2006

Invited Speaker at the CD38 Meeting, Turin, June 2006

2007:

Invited Speaker Keystone Symposia on Regulatory T cells, Vancouver, Canada, February 2007

Seminar at the Feinstein Institute, North Shore Hospital, Manhasset NY, March 2007

Invited Speaker at the annual SICICS Congress, Turin, November 2007

2008:

Invited lecture at the UK CLL Forum, London, April 2008

Invited Speaker at the IV International Workshop on CLL, Salzburg (Austria), May 2008

Invited Speaker at the XXVI Incontro di Aggiornamento e Formazione of the "Gruppo Italiano di Citometria", Urbino, October 2008

Invited Speaker at the X National Congresso of the Italian Society of Experimental Hematology (SIES), Bari, Italy, September 2008

Invited Speaker at the European School of Hematology (ESH) Conference on CLL, Barcelona, November 2008

2009:

Invited Seminar at the Lyon INSERM Unit 851 (Dr. Bonnefoye-Berard), March 2009

Invited Seminar at the PhD School of Biomolecular Sciences "Bios", University of Pisa.

Session organizer at the iwCLL Meeting, Barcellona, November 2009

2010:

Invited Seminar at the Seragnoli Institute, Bologna, January 2010

Invited Seminar at the Department of Hematology, Cardiff University, Cardiff, UK, February 2010

Session chair and Speaker at the HLDA9 Meeting, Barcelona, March 2010

Invited Speaker at the Henry Kunkel Society, The Rockefeller University, New York, April 2010

Invited Speaker at the GISL Conference on CLL, Cosenza (Italy), September 2010

2011

Invited Seminar at the Beth Israel Deaconess Medical Center, Harvard University, Boston, MA.

Invited Speaker at the 36th Congress of the Federation of European Biochemical Societies (FEBS), Turin, June 2011.

Invited Seminar at the Cancer Research UK London Institute, London, UK.

RESEARCH SUPPORT

Ongoing Research Support

Italian Association for Cancer Research (AIRC). (Investigator Grant 2009-2011).

"Nucleotide-metabolizing enzymes in the maintenance and progression of CLL: potential therapeutic applications?"

Role: PI (€ 80,000.00/2010).

Collaborative study involving the coordination of 4 national and 2 international Units

Compagnia di SanPaolo (2008-2010)

"Antigen-dependent and-independent mechanisms in the pathogenesis of chronic lymphocytic leukemia"

Role: PI of Operative Unit #3 (€ 60,000.00/2009; € 60,000.00/2010).

Collaborative project involving 3 Units.

Regione Piemonte (2009-2010)

“Cellular and molecular mechanisms in the progression of chronic lymphocytic leukemia: novel therapeutical approaches”

Role: PI (€ 6,000.00)

Human Genetics Foundation Investigator Grant 2010

“Genetic regulation, surface receptors and soluble molecules in the control of tumor/host interactions”

Role: PI (€ 190,000.00)

Collaborative project involving the coordination of 3 national and 2 international Units

Italian Ministry of Health, Young Investigator Grant 2008.

“Identification of novel prognostic factors and therapeutic targets for Richter's syndrome”

Role: PI (€ 500,000.00)

Collaborative project involving 5 Units

Italian Ministry of Education, Futuro in Ricerca 2008 Project

“Soluble factors, membrane receptors and genetic regulation in tumor/host interactions”

Role: PI (€ 373,000.00)

Collaborative project involving 3 Units, each coordinated by a young (<35) investigator.

Italian Ministry of Education, PRIN Project, 2009

“Coordinated expression of CD39 and CD73 by chronic lymphocytic leukemia catalyzes immunosuppression and contributes to create microenvironmental conditions favoring growth”

Role: PI of Operative Unit (€ 69,000.00) for 2 years

Collaborative project involving 4 Units, coordinated by Prof. F. Di Virgilio (University of Ferrara).

Completed Research Support

Progetti di Rilevanza e Interesse Nazionale (PRIN) 2005-2006:

“Identificazione, analisi molecolare ed attività funzionale di recettori di membrana e fattori citoplasmatici coinvolti nella crescita e differenziamento di cellule di leucemia linfatica cronica B: impatto sulla prognosi clinica”.

Role: PI of Operative Unit

(€ 28,000.00)

Grants from University of Torino School of Medicine (Fondi di Ateneo 2007-2009)

“Role of human CD38 in the growth and differentiation of normal and tumoral B lymphocytes. The model of chronic lymphocytic leukemia”.

Role: PI (€ 17,000)

Chronic Lymphocytic Leukemia Global Research Foundation (CLL-GRF 2006-2007)

“CD38 and the fate of CLL cells: innocent bystander or culprit?”

Role: PI (\$ 200,000)

Italian Association for Cancer Research (AIRC). (Investigator Grant 2007-2009)

“Combined role of CD38 and ZAP-70 in CLL: from pathogenesis, to diagnosis and therapy”

Role: PI (€ 30,000/2007; 50,000/2008; 70,000/2009)

Regione Piemonte (2008-2009)

“In vitro models to evaluate the therapeutic potential of anti-CD38 mAbs for CLL patients”.

Role: PI (€ 12,000.00)

PEER-REVIEWED PUBLICATIONS (1996-2011)

A. WITH IMPACT FACTOR

Total number of publications: 90

Total IF (JCR 2010): 546

Mean IF: 6.3

Total number of publications first/last author: 28

Total IF publications first/last author: 201

Mean IF publications first/last author: 7.4

- Deaglio, S., U. Dianzani, A. L. Horenstein, J. E. Fernandez, C. van Kooten, M. Bragardo, A. Funaro, G. Garbarino, F. Di Virgilio, J. Banchereau, and F. Malavasi. 1996. Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. *The Journal of Immunology* 156:727-734. IF: 5.64
2. Cesano, A., S. Visonneau, S. Deaglio, F. Malavasi, and D. Santoli. 1998. Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. *The Journal of Immunology* 160:1106-1115. IF: 5.64
 3. Deaglio, S., M. Morra, R. Mallone, C. M. Ausiello, E. Prager, G. Garbarino, U. Dianzani, H. Stockinger, and F. Malavasi. 1998. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. *The Journal of Immunology* 160:395-402. IF: 5.64
 4. Fernandez, J. E., S. Deaglio, D. Donati, I. S. Beusan, F. Corno, A. Aranega, M. Forni, B. Falini, and F. Malavasi. 1998. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. *The Journal of biological regulators and homeostatic agents* 12:81-91. IF: 3.167
 5. Baj, G., A. Arnulfo, S. Deaglio, E. Tibaldi, N. Surico, and F. Malavasi. 1999. All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. *Journal of biological regulators and homeostatic agents* 13:115-122. IF: 3.167
 6. Vallario, A., M. Chilosi, F. Adami, L. Montagna, S. Deaglio, F. Malavasi, and F. Caligaris-Cappio. 1999. Human myeloma cells express the CD38 ligand CD31. *British journal of haematology* 105:441-444. IF: 4.59

7. Ausiello, C. M., F. Urbani, R. Lande, A. la Sala, B. Di Carlo, G. Baj, N. Surico, J. Hilgers, S. Deaglio, A. Funaro, and F. Malavasi. 2000. Functional topography of discrete domains of human CD38. *Tissue antigens* 56:539-547. IF: 2.33
8. Baj, G., A. Arnulfo, S. Deaglio, R. Mallone, A. Vigone, M. Rosa, M. Giana, L. Villa, F. Malavasi, and N. Surico. 2000. Retinoids in breast cancer prevention and treatment. A review of the literature. *European journal of gynaecological oncology* 21:411-415. IF: 0.61
9. Cassoni, P., E. Fulcheri, M. L. Carcangiu, A. Stella, S. Deaglio, and G. Bussolati. 2000. Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. *The Journal of pathology* 190:470-477. IF: 6.466
10. Deaglio, S., R. Mallone, G. Baj, A. Arnulfo, N. Surico, U. Dianzani, K. Mehta, and F. Malavasi. 2000. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. *Chemical immunology* 75:99-120.
11. Zilber, M. T., S. Gregory, R. Mallone, S. Deaglio, F. Malavasi, D. Charron, and C. Gelin. 2000. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. *Proceedings of the National Academy of Sciences of the United States of America* 97:2840-2845. IF: 9.43
12. Cassoni, P., T. Marrocco, S. Deaglio, A. Sapino, and G. Bussolati. 2001. Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. *Annals of Oncology* 12 Suppl 2:S37-39. IF: 5.64
13. Cassoni, P., A. Sapino, L. Munaron, S. Deaglio, B. Chini, A. Graziani, A. Ahmed, and G. Bussolati. 2001. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. *Endocrinology* 142:1130-1136. IF: 4.75
14. Deaglio, S., D. Canella, G. Baj, A. Arnulfo, S. Waxman, and F. Malavasi. 2001. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As₂O₃) on myeloma cells. *Leukemia research* 25:227-235. IF: 2.35
15. Deaglio, S., R. Mallone, G. Baj, D. Donati, G. Giraud, F. Corno, S. Bruzzone, M. Geuna, C. Ausiello, and F. Malavasi. 2001. Human CD38 and its ligand CD31 define a

unique lamina propria T lymphocyte signaling pathway. *FASEB Journal* 15:580-582. IF: 6.4

16. Deaglio, S., K. Mehta, and F. Malavasi. 2001. Human CD38: a (r)evolutionary story of enzymes and receptors. *Leukemia research* 25:1-12. IF: 3.167
17. Morabito, F., M. Mangiola, B. Oliva, C. Stelitano, V. Callea, S. Deaglio, P. Iacopino, M. Brugiattelli, and F. Malavasi. 2001. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. *Leukemia research* 25:927-932. IF: 3.167
18. Musso, T., S. Deaglio, L. Franco, L. Calosso, R. Badolato, G. Garbarino, U. Dianzani, and F. Malavasi. 2001. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. *Journal of leukocyte biology* 69:605-612. IF: 4.403
19. Sapino, A., M. Bongiovanni, P. Cassoni, L. Righi, R. Arisio, S. Deaglio, and F. Malavasi. 2001. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. *The Journal of pathology* 194:254-261. IF: 6.466
20. Baj, G., A. Arnulfo, S. Deaglio, R. Mallone, A. Vigone, M. G. De Cesaris, N. Surico, F. Malavasi, and E. Ferrero. 2002. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. *Breast cancer research and treatment* 73:61-73. IF: 4.696
21. Cassoni, P., A. Sapino, S. Deaglio, B. Bussolati, M. Volante, L. Munaron, A. Albin, A. Torrisi, and G. Bussolati. 2002. Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. *Cancer research* 62:2406-2413. IF: 7.543
22. Deaglio, S., A. Capobianco, A. Cali, F. Bellora, F. Alberti, L. Righi, A. Sapino, C. Camaschella, and F. Malavasi. 2002. Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. *Blood* 100:3782-3789. IF: 10.555
23. Deaglio, S., M. Zubiaur, A. Gregorini, F. Bottarel, C. M. Ausiello, U. Dianzani, J. Sancho, and F. Malavasi. 2002. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. *Blood* 99:2490-2498. IF: 10.555

24. Gregorini, A., C. Cinti, F. Pigliapoco, S. Deaglio, E. Ferrero, S. Papa, and F. Palma. 2002. Rapid and sensitive detection of recombinant soluble proteins in the supernatant of transfected mammalian cells. *Journal of biological regulators and homeostatic agents* 16:93-97. IF: 3.167
25. Lande, R., F. Urbani, B. Di Carlo, G. Sconocchia, S. Deaglio, A. Funaro, F. Malavasi, and C. M. Ausiello. 2002. CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. *Cellular immunology* 220:30-38. IF: 2.698
26. Morabito, F., M. Mangiola, C. Stelitano, S. Deaglio, V. Callea, and F. Malavasi. 2002. Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil. *Haematologica* 87:217-218. IF: 6.416
27. Deaglio, S., A. Capobianco, L. Bergui, J. Durig, F. Morabito, U. Duhrsen, and F. Malavasi. 2003. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. *Blood* 102:2146-2155. IF: 10.555
28. Durig, J., H. Nuckel, A. Huttmann, E. Kruse, T. Holter, K. Halfmeyer, A. Fuhrer, R. Rudolph, N. Kalhori, A. Nusch, S. Deaglio, F. Malavasi, T. Moroy, L. Klein-Hitpass, and U. Duhrsen. 2003. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. *Blood* 101:2748-2755. IF: 10.555
29. Morabito, F., M. Mangiola, C. Stelitano, S. Deaglio, V. Callea, and F. Malavasi. 2003. Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome? *Haematologica* 88:354-355. IF: 6.416
30. Righi, L., S. Deaglio, C. Pecchioni, A. Gregorini, A. L. Horenstein, G. Bussolati, A. Sapino, and F. Malavasi. 2003. Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. *The American journal of pathology* 162:1163-1174. IF: 5.673
31. Savarino, A., T. Bensi, A. Chiocchetti, F. Bottarel, R. Mesturini, E. Ferrero, L. Calosso, S. Deaglio, E. Ortolan, S. Butto, A. Cafaro, T. Katada, B. Ensoli, F. Malavasi, and U. Dianzani. 2003. Human CD38 interferes with HIV-1 fusion through a sequence

- homologous to the V3 loop of the viral envelope glycoprotein gp120. *FASEB J* 17:461-463. IF: 6.4
32. Tenca, C., A. Merlo, D. Zarcone, D. Saverino, S. Bruno, A. De Santanna, D. Ramarli, M. Fabbi, C. Pesce, S. Deaglio, E. Ciccone, F. Malavasi, and C. E. Grossi. 2003. Death of T cell precursors in the human thymus: a role for CD38. *International immunology* 15:1105-1116. IF: 3.403
 33. Calzolari, A., S. Deaglio, N. M. Sposi, E. Petrucci, O. Morsilli, M. Gabbianelli, F. Malavasi, C. Peschle, and U. Testa. 2004. Transferrin receptor 2 protein is not expressed in normal erythroid cells. *The Biochemical journal* 381:629-634. IF: 5.155
 34. Deaglio, S., T. Vaisitti, L. Bergui, L. Bonello, A. L. Horenstein, L. Tamagnone, L. Boumsell, and F. Malavasi. 2005. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. *Blood* 105:3042-3050. IF: 10.555
 35. Isoardo, G., S. Deaglio, D. Cocito, G. Migliaretti, E. Ferrero, F. Cavallo, L. Durelli, and F. Malavasi. 2005. Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. *Journal of neuroimmunology* 161:78-86. IF: 2.841
 36. Vaisitti, T., S. Deaglio, and F. Malavasi. 2005. Cationization of monoclonal antibodies: another step towards the "magic bullet"? *Journal of biological regulators and homeostatic agents* 19:105-112. IF: 3.167
 37. Calzolari, A., C. Raggi, S. Deaglio, N. M. Sposi, M. Stafsnes, K. Fecchi, I. Parolini, F. Malavasi, C. Peschle, M. Sargiacomo, and U. Testa. 2006. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. *Journal of cell science* 119:4486-4498. IF: 6.144
 38. Deaglio, S., and F. Malavasi. 2006. The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes. *Purinergic Signalling* 2:431-441. IF: 2.87
 39. Deaglio, S., T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi. 2006. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. *Blood* 108:1135-1144. IF: 10.555

40. Frasca, L., G. Fedele, S. Deaglio, C. Capuano, R. Palazzo, T. Vaisitti, F. Malavasi, and C. M. Ausiello. 2006. CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. *Blood* 107:2392-2399. IF: 10.555
41. Malavasi, F., S. Deaglio, E. Ferrero, A. Funaro, J. Sancho, C. M. Ausiello, E. Ortolan, T. Vaisitti, M. Zubiaur, G. Fedele, S. Aydin, E. V. Tibaldi, I. Durelli, R. Lusso, F. Cozno, and A. L. Horenstein. 2006. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. *Molecular Medicine* 12:334-341. IF: 5.02
42. Morabito, F., R. N. Damle, S. Deaglio, M. Keating, M. Ferrarini, and N. Chiorazzi. 2006. The CD38 ectoenzyme family: advances in basic science and clinical practice. *Molecular Medicine* 12:342-344. IF: 5.02
43. Calzolari, A., I. Oliviero, S. Deaglio, G. Mariani, M. Biffoni, N. M. Sposi, F. Malavasi, C. Peschle, and U. Testa. 2007. Transferrin receptor 2 is frequently expressed in human cancer cell lines. *Blood Cells Molecules and Diseases* 39:82-91. IF: 2.901
44. D'Arena, G., M. Tarnani, C. Rumi, T. Vaisitti, S. Aydin, R. De Filippi, F. Perrone, A. Pinto, P. Chiusolo, S. Deaglio, F. Malavasi, and L. Laurenti. 2007. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. *American Journal of Hematology* 82:787-791. IF: 2.61
45. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, and S. C. Robson. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *Journal of Experimental Medicine* 204:1257-1265. IF: 14.505
46. Deaglio, S., T. Vaisitti, S. Aydin, L. Bergui, G. D'Arena, L. Bonello, P. Omede, M. Scatolini, O. Jaksic, G. Chiorino, D. Efremov, and F. Malavasi. 2007. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. *Blood* 110:4012-4021. IF: 10.555
47. Deaglio, S., T. Vaisitti, R. Billington, L. Bergui, P. Omede, A. A. Genazzani, and F. Malavasi. 2007. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. *Blood* 109:5390-5398. IF: 10.555

48. Dwyer, K. M., S. Deaglio, W. Gao, D. Friedman, T. B. Strom, and S. C. Robson. 2007. CD39 and control of cellular immune responses. *Purinergic Signalling* 3:171-180. IF: 2.87
49. Willimott, S., M. Baou, S. Huf, S. Deaglio, and S. D. Wagner. 2007. Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. *Haematologica* 92:1359-1366. IF: 6.416
50. Aydin, S., D. Rossi, L. Bergui, G. D'Arena, E. Ferrero, L. Bonello, P. Omede, D. Novero, F. Morabito, A. Carbone, G. Gaidano, F. Malavasi, and S. Deaglio. 2008. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? *Blood* 111:5646-5653. IF: 10.555
51. Deaglio, S., S. Aydin, T. Vaisitti, L. Bergui, and F. Malavasi. 2008. CD38 at the junction between prognostic marker and therapeutic target. *Trends in Molecular Medicine* 14:210-218. IF: 11.049
52. Malavasi, F., S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin. 2008. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiological Reviews* 88:841-886. IF: 37.726
53. Sitkovsky, M., D. Lukashev, S. Deaglio, K. Dwyer, S. C. Robson, and A. Ohta. 2008. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. *British Journal of Pharmacology* 153 Suppl 1:S457-464. IF: 5.204
54. Calzolari, A., V. Finisguerra, I. Oliviero, S. Deaglio, G. Mariani, F. Malavasi, and U. Testa. 2009. Regulation of transferrin receptor 2 in human cancer cell lines. *Blood Cells Molecules and Diseases* 42:5-13. IF: 2.901
55. Calzolari, A., S. Deaglio, E. Maldi, P. Cassoni, F. Malavasi, and U. Testa. 2009. TfR2 expression in human colon carcinomas. *Blood Cells Molecules and Diseases*. 43:243-249. IF: 2.901
56. Dal-Bo, M., F. Bertoni, F. Forconi, A. Zucchetto, R. Bomben, R. Marasca, S. Deaglio, L. Laurenti, D. G. Efremov, G. Gaidano, G. Del Poeta, and V. Gattei. 2009. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. *Journal of Translational Medicine* 7:76. IF: 3.407

57. Deaglio, S., and F. Malavasi. 2009. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. *Haematologica* 94:752-756. IF: 6.416
58. Horenstein, A. L., F. Sizzano, R. Lusso, F. G. Besso, E. Ferrero, S. Deaglio, F. Corno, and F. Malavasi. 2009. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. *Molecular Medicine* 15:76-84. IF: 5.02
59. Rossi, D., V. Spina, M. Cerri, S. Rasi, C. Deambrogi, L. De Paoli, L. Laurenti, R. Maffei, F. Forconi, F. Bertoni, E. Zucca, C. Agostinelli, A. Cabras, M. Lucioni, M. Martini, M. Magni, S. Deaglio, M. Ladetto, J. F. Nomdedeu, C. Besson, A. Ramponi, V. Canzonieri, M. Paulli, R. Marasca, L. M. Larocca, A. Carbone, S. A. Pileri, V. Gattei, and G. Gaidano. 2009. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome. *Clinical Cancer Research* 15:4415-4422. IF: 6.747
60. Zucchetto, A., D. Benedetti, C. Tripodo, R. Bomben, M. Dal Bo, D. Marconi, F. Bossi, D. Lorenzon, M. Degan, F. M. Rossi, D. Rossi, P. Bulian, V. Franco, G. Del Poeta, S. Deaglio, G. Gaidano, F. Tedesco, F. Malavasi, and V. Gattei. 2009. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. *Cancer Research* 69:4001-4009. IF: 7.543
61. De Martino, L., G. D'Arena, M.M. Minervini, S. Deaglio, B.M. Fusco, N. Cascavilla, and V. De Feo. 2009. Verbena officinalis essential oil and its component citral as apoptotic-inducing agent in chronic lymphocytic leukemia. *International Journal of Immunopathology and Pharmacology* 22:1097-1104. IF: 3.061
62. Calzolari, A., L.M. Larocca, S. Deaglio, V. Finisguerra, A. Boe, C. Raggi, L. Ricci-Vitani, F. Pierconti, F. Malavasi, R. De Maria, U. Testa, and R. Pallini. 2010. Transferrin receptor 2 is frequently and highly expressed in glioblastomas. *Translational Oncology* 3:123-134. IF: 2,4
63. Deaglio, S., S. Aydin, M.M. Grand, T. Vaisitti, L. Bergui, G. D'Arena, G. Chiorino, and F. Malavasi. 2010. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. *Molecular Medicine* 16:87-91. IF: 5.02

64. Pearce, L., L. Morgan, T.T. Lin, S. Hewamana, R.J. Matthews, S. Deaglio, C. Rowntree, C. Fegan, C. Pepper, and P. Brennan. 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. *Haematologica* 95:514-517. IF: 6.416
65. Vaisitti, T., S. Aydin, D. Rossi, F. Cottino, L. Bergui, G. D'Arena, L. Bonello, A.L. Horenstein, P. Brennan, C. Pepper, G. Gaidano, F. Malavasi, and S. Deaglio. 2010. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. *Leukemia* 24:958-969. IF: 8.296
66. Zucchetto, A., C. Tripodo, D. Benedetti, S. Deaglio, G. Gaidano, G. Del Poeta, and V. Gattei. 2010. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. *British journal of haematology* 150:111-113. IF: 4.597
67. Bulian, P., M. Tarnani, D. Rossi, F. Forconi, G. Del Poeta, F. Bertoni, E. Zucca, M. Montillo, G. Pozzato, S. Deaglio, G. D'Arena, D. Efremov, R. Marasca, F. Lauria, V. Gattei, G. Gaidano, and L. Laurenti. 2011. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. *Hematological oncology* 29:91-99. IF: 1.869
68. D'Arena, G., L. Laurenti, M.M. Minervini, S. Deaglio, L. Bonello, L. De Martino, L. De Padua, N.P. Sinisi, M. Tarnani, B.M. Fusco, V. De Feo, and N. Cascavilla. 2010. REGULATORY T-CELL NUMBER IS CORRELATED WITH PROGRESSIVE FEATURES OF DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. *Leukemia Research*, in press. IF: 2.358
69. Kunzli, B.M., P.O. Berberat, K. Dwyer, S. Deaglio, E. Csizmadia, P. Cowan, A. d'Apice, G. Moore, K. Enyoji, H. Friess, and S.C. Robson. 2011. Variable Impact of CD39 in Experimental Murine Colitis. *Dig Dis Sci* 56:1393-1403. IF: 2.06.
70. Malavasi, F., S. Deaglio, G. Zaccarello, A. Horenstein, A. Chillemi, V. Audrito, S. Serra, M. Gandione, A. Zitella, and A. Tizzani. 2010. The hidden life of NAD⁺-consuming ectoenzymes in the endocrine system. *Journal of Molecular Endocrinology* in press. IF: 3.221

71. Deaglio, S., T. Vaisitti, A. Zucchetto, V. Gattei, and F. Malavasi. 2010. CD38 as a molecular compass driving topographical decisions of chronic lymphocytic leukemia cells. *Seminars in Cancer Biology* in press. IF: 6.918
72. D'Arena, G., S. Capalbo, L. Laurenti, G. Del Poeta, G. Nunziata, S. Deaglio, G. Spinosa, M. Tarnani, L. De Padua, C. Califano, F. Ferrara, and N. Cascavilla. 2010. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. *European Journal of Haematology* 85:502-507. IF: 2.345
73. Dwyer, K.M., D. Hanidziar, P. Putheti, P.A. Hill, S. Pommey, J.L. McRae, A. Winterhalter, G. Doherty, S. Deaglio, M. Koulmanda, W. Gao, S.C. Robson, and T.B. Strom. 2010. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. *American Journal of Transplantation* 10:2410-2420. IF: 6.433
74. Saborit-Villarroya, I., T. Vaisitti, D. Rossi, G. D'Arena, G. Gaidano, F. Malavasi, and S. Deaglio. 2011. E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. *Leukemia* 25:479-488. IF: 8.96
75. D'Arena, G., L. Laurenti, M.M. Minervini, S. Deaglio, L. Bonello, L. De Martino, L. De Padua, L. Savino, M. Tarnani, V. De Feo, and N. Cascavilla. 2011. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. *Leukemia research* 35:363-368. IF: 2.66
76. Rasi, S., V. Spina, A. Brusca, T. Vaisitti, C. Tripodo, F. Forconi, L. De Paoli, M. Fangazio, E. Sozzi, E. Cencini, L. Laurenti, R. Marasca, C. Visco, Z.Y. Xu-Monette, V. Gattei, K.H. Young, F. Malavasi, S. Deaglio, G. Gaidano, and D. Rossi. 2011. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. *British journal of haematology* 152:284-294. IF: 4.94
77. Vaisitti, T., V. Audrito, S. Serra, C. Bologna, D. Brusa, F. Malavasi, and S. Deaglio. 2011. NAD(+)-metabolizing ecto-enzymes shape tumor-host interactions: The chronic lymphocytic leukemia model. *FEBS Lett* 585:1514-1520. IF: 3.60
78. Deaglio, S., and S.C. Robson. 2011. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. *Adv Pharmacol* 61:301-332.

79. Sandini, S., R. La Valle, S. Deaglio, F. Malavasi, A. Cassone, and F. De Bernardis. 2011. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of *Candida albicans* as a mucosal anticandidal vaccine. *FEMS immunology and medical microbiology* 62:215-224. IF: 2,49
80. Pezzolo, A., F. Parodi, D. Marimpietri, L. Raffaghello, C. Cocco, A. Pistorio, M. Mosconi, C. Gambini, M. Cilli, S. Deaglio, F. Malavasi, and V. Pistoia. 2011. Oct-4(+)/Tenascin C(+) neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. *Cell research* 21:1470-1486. IF: 9.41
81. Laurenti, L., L. De Padua, G. D'Arena, B. Vannata, I. Innocenti, M. Tarnani, S. Deaglio, S. Sica, D.G. Efremov, and G. Leone. 2011. New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia. *Mini reviews in medicinal chemistry* 11:508-518. IF: 2.62
82. D'Arena, G., S. Deaglio, L. Laurenti, L. De Martino, V. De Feo, B.M. Fusco, A.M. Carella, N. Cascavilla, and P. Musto. 2011a. Targeting regulatory T cells for anticancer therapy. *Mini reviews in medicinal chemistry* 11:480-485. IF: 2.62
83. Deaglio, S., T. Vaisitti, S. Serra, V. Audrito, C. Bologna, G. D'Arena, L. Laurenti, D. Gottardi, and F. Malavasi. 2011. CD38 in chronic lymphocytic leukemia: from bench to bedside? *Mini reviews in medicinal chemistry* 11:503-507. IF: 2.62
84. Crowther-Swanepoel, D., M.C. Di Bernardo, K. Jamroziak, L. Karabon, I. Frydecka, S. Deaglio, G. D'Arena, D. Rossi, G. Gaidano, B. Olver, A. Lloyd, P. Broderick, L. Laurenti, Z. Szemraj-Rogucka, T. Robak, D. Catovsky, and R.S. Houlston. 2011. Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. *British journal of haematology* 154:229-233. IF: 4.94
85. Ferretti, E., M. Bertolotto, S. Deaglio, C. Tripodo, D. Ribatti, V. Audrito, F. Blengio, S. Matis, S. Zupo, D. Rossi, L. Ottonello, G. Gaidano, F. Malavasi, V. Pistoia, and A. Corcione. 2011. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. *Leukemia* 25:1268-1277. IF: 8.96
86. Audrito, V., T. Vaisitti, D. Rossi, D. Gottardi, G. D'Arena, L. Laurenti, G. Gaidano, F. Malavasi, and S. Deaglio. 2011. Nicotinamide blocks proliferation and induces apoptosis

of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. *Cancer research* 71:4473-4483 IF: 8.23

87. Malavasi, F., S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, and N. Chiorazzi. 2011. CD38 and chronic lymphocytic leukemia: a decade later. *Blood* 118:3470-3478. IF: 10.56
88. D'Arena, G., L. Laurenti, M.M. Minervini, S. Deaglio, L. Bonello, L. De Martino, L. De Padua, L. Savino, M. Tarnani, V. De Feo, and N. Cascavilla. 2011b. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. *Leukemia research* 35:363-368.
89. Rossi, D., S. Deaglio, D. Dominguez-Sola, S. Rasi, T. Vaisitti, C. Agostinelli, V. Spina, A. Brusca, S. Monti, M. Cerri, S. Cresta, M. Fangazio, L. Arcaini, M. Lucioni, R. Marasca, C. Thieblemont, D. Capello, F. Facchetti, I. Kwee, S.A. Pileri, R. Foa, F. Bertoni, R. Dalla-Favera, L. Pasqualucci, and G. Gaidano. 2011. Alteration of BIRC3 and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. *Blood*, in press. IF: 10.56
90. Serra, S., A. Horenstein, V. T., D. Brusa, D. Rossi, L. Laurenti, G. D'Arena, M. Coscia, C. Tripodo, G. Inghirami, S.C. Robson, G. Gaidano, F. Malavasi, and D. S. 2011. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. *Blood*, in press. IF: 10.56

B. PUBBLICAZIONI SCIENTIFICHE SU RIVISTE SENZA IMPACT FACTOR

1. F. Malavasi, **S. Deaglio**, M. Morra, G. Di Rosa, E. Tibaldi, R. Mallone, L. Calosso, A. Zanotto, and L. Saturni.
Monoclonal Antibodies.
Minerva Biotecnologica 8: 55-57, 1996.
2. **S. Deaglio**, R. Mallone, G. Baj, A. Arnulfo, E. Ortolan, L. Calosso, C. Ausiello, F. Saccucci, A. Gregorini, C. Cinti, A. Horenstein, M. Zubiaur, J. Sancho, U. Dianzani, E. Ferrero, A. Funaro, T. Katada, K. Mehta, and F. Malavasi.
Signaling and activation, calcium and cytokine release, receptorial activities of the human CD38 family of NAD⁺-converting ectoenzymes.
Research Trends 2:19-36, 1999.
3. D. Alioto, M. Gangemi, **S. Deaglio**, P. Sposato, E. Noris, E. Luisoni, and R.G. Milne.
Improved detection of citrus psorosis virus using polyclonal and monoclonal antibodies.
Plant Pathology 48: 735-741, 1999.
4. **S. Deaglio** and F. Malavasi
Human CD38: a receptor, an (ecto)enzyme, a disease marker and lots more
Modern Aspects of Immunobiology 2: 121-125, 2002.
5. **S. Deaglio** and F. Malavasi
The CD38/CD157 mammalian gene family: an evolutionary paradigm for other leukocyte surface enzymes
Purinergic Signaling, 2006, 2:431-441.
6. K.M. Dwyer, **S. Deaglio**, W. Gao, D. Friedman, T.B. Strom and S.C. Robson
CD39 and control of cellular immune responses.
Purinergic Signaling, 2007, 3:171-180.

C. CAPITOLI DI LIBRI

1. M. Morra, **S. Deaglio**, R. Mallone, G. Di Rosa, E. Tibaldi, G. Zini, C. Cinti, M. Reinis, A. Horenstein, E. Ferrero, A. Funaro, and F. Malavasi.

CD38 cluster report.

In: Human Leukocyte Differentiation Antigens VI, T. Kishimoto, H. Kikutani, A. E.G. Kr. Von dem Borne, S. M. Goyert, D. Y. Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T. A. Springer, K. Sugamura and H. Zola Editors. Garland Publishing, Inc., New York, N.Y., p.: 151-154, 1998.

2. M. Morra, **S. Deaglio**, L. Calosso, M. Gagliardi, and F. Malavasi.
Anticorpi monoclonali.
In: Radioimmunodiagnostica e tumori del colon-retto. F. Badellino e A. Zonta Editors. Piccin Publisher, Padova, Italy, p 25-36, 1999.
3. M. Donadio, **S. Deaglio**, D. Marengo, and O. Bertetto.
La compliance terapeutica.
In: Psicooncologia. M. Bellani, G. Morasso, D. Amadori, W. Orru`, L. Grassi, P.G. Casali, and P.D. Bruzzi Editors. Masson Publisher, Milano, Italy, 2001, chapter 23.
- 4) A. Sapino, L. Righi, P. Cassoni, M. Bongiovanni, **S. Deaglio**, and F. Malavasi.
CD31 is expressed by cells of ductal in situ carcinomas of the breast.
In: Human Leukocyte Differentiation Antigens VII, 1D. Mason, P. André, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. De Haas, S. Goyert, M. Hadam, D. Hart, V. Horejsi, Y. Jones, S. Meuer, J. Morrissey, R. Schwartz-Albiez, S. Shaw, D. Turni, M. Ugucioni, E. Van Der Schoot, E. Vivier, and H. Zola Editors, Pergamon Press, Oxford, UK, p. 227-229, 2002.
5. **S. Deaglio**, R. Mallone, G. Baj, D. Donati, G. Girauda, F. Corno, M. Geuna, C. Ausiello, and F. Malavasi.
CD38 signaling in *lamina propria* diverges from that of circulating T lymphocytes in selected steps.
In: Human Leukocyte Differentiation Antigens VII, 1D. Mason, P. André, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. De Haas, S. Goyert, M. Hadam, D. Hart, V. Horejsi, Y. Jones, S. Meuer, J. Morrissey, R. Schwartz-Albiez, S. Shaw, D. Turni, M. Ugucioni, E. Van Der Schoot, E. Vivier, and H. Zola Editors, Pergamon Press, Oxford, UK, p. 705-707, 2002.
6. **S. Deaglio**, P. Sposato, E. Barisone, U. Ramenghi, K. Ishihara, T. Katada, and F. Malavasi.
Analysis of human CD157 by means of murine mAbs

In: Human Leukocyte Differentiation Antigens VII, 1D. Mason, P. André, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. De Haas, S. Goyert, M. Hadam, D. Hart, V. Horejsi, Y. Jones, S. Meuer, J. Morrissey, R. Schwartz-Albiez, S. Shaw, D. Turni, M. Ugucioni, E. Van Der Schoot, E. Vivier, and H. Zola Editors, Pergamon Press, Oxford, UK, p. 368-369, 2002.

7. **S. Deaglio**, G. Baj, A. Arnulfo, and F. Malavasi.
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As₂O₃) on myeloma cells
In: Human Leukocyte Differentiation Antigens VII, 1D. Mason, P. André, A. Bensussan, C. Buckley, C. Civin, E. Clark, M. De Haas, S. Goyert, M. Hadam, D. Hart, V. Horejsi, Y. Jones, S. Meuer, J. Morrissey, R. Schwartz-Albiez, S. Shaw, D. Turni, M. Ugucioni, E. Van Der Schoot, E. Vivier, and H. Zola Editors, Pergamon Press, Oxford, UK, p. 676-677, 2002.

8. **S. Deaglio** and S.C. Robson
Extracellular nucleotides and nucleosides as autocrine and paracrine regulators within the vasculature.
In: Endothelial Biomedicine: A Comprehensive Reference. W.C. Aird. Editor, Cambridge University Press, p. 384-396, 2007.

9. **S. Deaglio** and R. Damle
CD38: From Prognostic Marker to Disease Modulator in Chronic Lymphocytic Leukemia.
In: New Biological Markers in CLL. P. Ghia, K. Stamatopoulos and R. Rosenquist Editors, Wolter-Kluwer Pbs, 2010 in press.